FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947428043> ?p ?o ?g. }

• W2947428043 abstract "1010 Background: Markers of early progression on endocrine therapy in combination with CDK4/6 inhibitors remain limited despite the key role of these combinations in treating of ER+ advanced breast cancer (ABC). We investigated genomic aberrations in patients treated with fulvestrant, with and without palbociclib, with a circulating tumor DNA analysis of baseline plasma in the PALOMA-3 trial. Methods: PALOMA-3 was a phase III trial that randomized 521 patients with ER+/HER2- ABC 2:1 to palbociclib plus fulvestrant (P+F) or placebo plus fulvestrant (F). Using baseline plasma samples, somatic mutations were assessed with a 17 gene panel. Copy number aberrations (CNA) were characterized with a 14 gene panel including ~800 SNPs in 8 commonly altered regions for estimation of tumor purity, the percentage of plasma DNA that was derived from tumor cells. Results for mutations and CNAs were available in 310 pts (203 P+F, 107 F) and were associated with clinical characteristics and progression free survival (PFS) using univariable and multivariable Cox proportional hazards models, including tumor purity and treatment as variables. Results: In the multivariable analysis of the whole cohort, higher baseline tumor purity in plasma was associated with worse PFS (HR 1.20, 95% CI 1.09 – 1.32, p = 0.0001, HR per 10% increase in purity). Baseline TP53 mutation was also associated with shorter PFS (HR 1.84, 95%CI 1.27 – 2.65, p = 0.0011), as was baseline FGFR1 amplification (HR 2.91, 95%CI 1.61 – 5.25, p = 0.0004). PIK3CA and ESR1 mutations had no significant association with PFS in the multivariable model. Palbociclib treatment effect was comparable with the overall trial result (HR 0.43, 95%CI 0.32 - 0.57, p < 0.0001). TP53 mutations were significantly associated with visceral (q = 0.046) and soft tissue/LN metastases (q = 0.042) and the number of disease sites (q = 0.0086) after correction for multiple testing. Conclusions: TP53 mutation, FGFR1 amplification , and tumor purity in plasma identified patients at risk of early progression In PALOMA-3. If validated these results could inform future clinical trials of CDK4/6 inhibitors combinations." @default.
• W2947428043 created "2019-06-07" @default.
• W2947428043 creator A5001814176 @default.
• W2947428043 creator A5010278367 @default.
• W2947428043 creator A5018557915 @default.
• W2947428043 creator A5027068050 @default.
• W2947428043 creator A5032987754 @default.
• W2947428043 creator A5038065865 @default.
• W2947428043 creator A5046214153 @default.
• W2947428043 creator A5047768231 @default.
• W2947428043 creator A5056846110 @default.
• W2947428043 creator A5060044961 @default.
• W2947428043 creator A5075134210 @default.
• W2947428043 creator A5087559224 @default.
• W2947428043 date "2019-05-20" @default.
• W2947428043 modified "2023-10-05" @default.
• W2947428043 title "Genomic markers of early progression on fulvestrant with or without palbociclib for ER+ advanced breast cancer in the PALOMA-3 trial." @default.
• W2947428043 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.1010" @default.
• W2947428043 hasPublicationYear "2019" @default.
• W2947428043 type Work @default.
• W2947428043 sameAs 2947428043 @default.
• W2947428043 citedByCount "7" @default.
• W2947428043 countsByYear W29474280432019 @default.
• W2947428043 countsByYear W29474280432021 @default.
• W2947428043 crossrefType "journal-article" @default.
• W2947428043 hasAuthorship W2947428043A5001814176 @default.
• W2947428043 hasAuthorship W2947428043A5010278367 @default.
• W2947428043 hasAuthorship W2947428043A5018557915 @default.
• W2947428043 hasAuthorship W2947428043A5027068050 @default.
• W2947428043 hasAuthorship W2947428043A5032987754 @default.
• W2947428043 hasAuthorship W2947428043A5038065865 @default.
• W2947428043 hasAuthorship W2947428043A5046214153 @default.
• W2947428043 hasAuthorship W2947428043A5047768231 @default.
• W2947428043 hasAuthorship W2947428043A5056846110 @default.
• W2947428043 hasAuthorship W2947428043A5060044961 @default.
• W2947428043 hasAuthorship W2947428043A5075134210 @default.
• W2947428043 hasAuthorship W2947428043A5087559224 @default.
• W2947428043 hasConcept C121608353 @default.
• W2947428043 hasConcept C126322002 @default.
• W2947428043 hasConcept C143998085 @default.
• W2947428043 hasConcept C2775930923 @default.
• W2947428043 hasConcept C2776694085 @default.
• W2947428043 hasConcept C2779744173 @default.
• W2947428043 hasConcept C2780482068 @default.
• W2947428043 hasConcept C2780739268 @default.
• W2947428043 hasConcept C530470458 @default.
• W2947428043 hasConcept C71924100 @default.
• W2947428043 hasConcept C84606932 @default.
• W2947428043 hasConceptScore W2947428043C121608353 @default.
• W2947428043 hasConceptScore W2947428043C126322002 @default.
• W2947428043 hasConceptScore W2947428043C143998085 @default.
• W2947428043 hasConceptScore W2947428043C2775930923 @default.
• W2947428043 hasConceptScore W2947428043C2776694085 @default.
• W2947428043 hasConceptScore W2947428043C2779744173 @default.
• W2947428043 hasConceptScore W2947428043C2780482068 @default.
• W2947428043 hasConceptScore W2947428043C2780739268 @default.
• W2947428043 hasConceptScore W2947428043C530470458 @default.
• W2947428043 hasConceptScore W2947428043C71924100 @default.
• W2947428043 hasConceptScore W2947428043C84606932 @default.
• W2947428043 hasLocation W29474280431 @default.
• W2947428043 hasOpenAccess W2947428043 @default.
• W2947428043 hasPrimaryLocation W29474280431 @default.
• W2947428043 hasRelatedWork W2751810360 @default.
• W2947428043 hasRelatedWork W2931385471 @default.
• W2947428043 hasRelatedWork W2944002023 @default.
• W2947428043 hasRelatedWork W3093743109 @default.
• W2947428043 hasRelatedWork W3139237627 @default.
• W2947428043 hasRelatedWork W3203690439 @default.
• W2947428043 hasRelatedWork W4248789801 @default.
• W2947428043 hasRelatedWork W4282924254 @default.
• W2947428043 hasRelatedWork W4322772104 @default.
• W2947428043 hasRelatedWork W4386328992 @default.
• W2947428043 isParatext "false" @default.
• W2947428043 isRetracted "false" @default.
• W2947428043 magId "2947428043" @default.
• W2947428043 workType "article" @default.